Logo

Jason Flowerday

Sep 28, 2016

3D Signatures has appointed Jason Flowerday as CEO. He succeeds Ferenc Somogyvari, who will remain on the company's board of directors. Flowerday has more than a decade of business development and marketing experience in the life sciences, including leadership experience at Bayer and Johnson and Johnson. He has also held executive leadership and entrepreneurial roles with Knight Therapeutics and Pro Bono Bio. Additionally, Flowerday was co-founder and co-owner of both Orphan Canada and RxMedia Healthcare Communications, and he is an independent director of Aequus Pharmaceuticals. 

Breaking News
The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.